相关实验视频

Updated: Jun 28, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

在复发/逆转性多发性骨髓瘤中治疗细胞因子释放综合征的护理考虑:来自MajesTEC-1研究的Teclistamab的经验

Donna Catamero¹, Patricia Blázquez Benito², Samantha Shenoy³

¹Associate Director, Myeloma Research, Adjunct Faculty, Mount Sinai Phillips School of Nursing, The Mount Sinai Health System, New York, NY.

Seminars in oncology nursing

|April 10, 2024

概括

在接受teclistamab的患者中,护士在管理细胞因子释放综合征 (CRS) 中发挥着至关重要的作用. 本综述为CRS诊断,监测和管理提供了实际指导,从临床试验和现实世界护理经验中汲取.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

细胞因子释放综合征 (CRS) 是对T细胞重定向疗法的常见系统性炎症反应.
德克利斯塔马布是一种用于复发性/耐药性多发性髓瘤的T细胞重定向疗法.
有效的CRS管理对于患者的安全和治疗的延续至关重要.

研究的目的:

为护士提供关于诊断,监测和CRS的管理的实用指南.
分享来自MajesTEC-1临床试验和现实生活护理实践的见解.
强调护士在CRS早期识别和支持性护理中的作用.

主要方法:

这项研究涉及对MajesTEC-1一半期临床试验数据的分析.
一项来自学术机构的护士调查提供了对CRS管理的真实见解.
在MajesTEC-1中,对患者进行了早期CRS症状的监测,在teclistamab给药之前需要发烧缓解.

主要成果:

在MajesTEC-1试验中,72%的患者经历了CRS,大多数病例是低度的.
所有的CRS事件都得到解决,没有一个病例导致治疗中止.
对CRS的现实支持措施与临床试验中确定的措施保持一致.

结论:

护士在CRS患者的前线护理中至关重要,需要迅速识别和适当的支持性治疗.
本综述为在接受teclistamab.患者中管理CRS的护士提供了实际指导.
这些发现强调了建立协议和护理警在有效管理CRS方面的重要性.

关键词:

双特异性抗体双特异性抗体细胞因子释放综合征是什么复发性/耐药性多发性骨髓瘤机械师是没有的.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...